1 / 41

Health R esearch with the EU - Horizon 2020 -

Health R esearch with the EU - Horizon 2020 - . Canadian Institutes of Health Research January 2014. CIHR Overview: Supporting Health Research Excellence. CIHR Mandate:

carys
Télécharger la présentation

Health R esearch with the EU - Horizon 2020 -

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Health Research with the EU - Horizon 2020 - Canadian Institutes of Health Research January 2014

  2. CIHR Overview: Supporting Health Research Excellence • CIHR Mandate: • “To excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system…” • Supports the work of approximately 14,000 researchers and trainees in universities, teaching hospitals, and research institutions across Canada; • Funds research that aims to improve Canadians’ health, health care system, and quality of life; • Fosters commercialization and knowledge translation: moving research discoveries from academic setting to the marketplace.

  3. Nutrition, Metabolism and Diabetes Musculoskeletal Health and Arthritis Population and Public Health Gender and Health Circulatory and Respiratory Health Cancer Research Aboriginal Peoples’ Health Genetics Neurosciences, Mental Health and Addiction Human Development, Child and Youth Health Health Services and Policy Research Infection and Immunity Aging CIHR: Addressing Health Research Priorities • Created in 2000, CIHR is a • unique model for health • research • With its 13 Institutes, CIHR has • become a meeting ground for • Canada’s health research • community • The model enables optimal • use of existing knowledge to fill • research gaps, maximize • cooperation and minimize • duplication

  4. CIHR’s International Engagement • The CIHR Act states that CIHR “should be an international leader in contributing to the global advancement of health research.” • CIHR's Strategic Plan proposes to pursue opportunities for international collaborations and lists the following objectives : • attract and retain the best international scholars and experts • connect trainees and researchers at the international level • focus on targeted collaborations/consortia that support Canada’s strengths and priorities • facilitate health research capacity building in low- and middle-income countries • address internationally recognized global health priorities

  5. CIHR’s Signature Initiatives: International Partnership CIHR’s Signature Initiatives are a successful mechanism to engage with international stakeholders and build partnerships in areas of shared priority Strategy for Patient-Oriented Research (SPOR) Personalized Medicine Pathways to Health Equity for Aboriginal Peoples Community-Based Primary Health Care International Collaborative Research Strategy for Alzheimer’s Disease Inflammation in Chronic Disease Canadian Epigenetics, Environment and Health Research Consortium Evidence-Informed Health Care 5

  6. Canada’s Participation in Framework Program 7 • Canadian Health Researchers Participation in FP7 • Overall 1118 Canadians (all areas) participated in 1023 applications, including 56 applicants in 46 health-related proposals • 298 Canadians participants in 255 projects with 27% rate successfor Canadian applications • 28 Canadian participants in 21 health-related projects with a near 50% success rate • Canada in FP7 • National Contact Points (NCP) • Coordination and Support Actions • ERA-NETs • Joint Programming Initiatives

  7. The EU Framework Programme for Research and Innovation Horizon 2020

  8. Why participate • Horizon 2020 is “Open” – Canada needs to partner • EU Strategy for International Cooperation under H2020 – Canada is a valued partner • Growing need for international cooperation to address complex scientific challenges and share high-cost projects • Creation of global research and innovation networks enables working with the best in the world • EU and Canada lead developments in a number of sectors among which the health sector • We have strong trade relations, and are powerful players in terms of industrial, technological and R&D capability

  9. What’s New? • A single program to support research and innovation bringing together formerly separate initiatives – a stronger and clearer focus (FP7+CIP+EIT) • Strong focus on societal challenges • More innovation and risk taking • Simplified access for all companies, universities, institutes in all EU countries and open to the rest of the world • More open, light & fast schemes • And The Same? • Canadians need to bring expertise to the project not available in Europe and self-funded • Research proposals still need at least 3 European researchers/entities from 3 different countries Horizon 2020

  10. Three main pillars Excellent science Industrial leadership Societal challenges

  11. Excellent Science • EuropeanResearch Council (ERC) • 1 researcher; 1 host institution; 1 project; 1 selection criterion: scientific excellence • No consortia, no networks, no co-financing • Applications can be made in any field of research • Independent researchers from anywhere in the world, of any age and career stage can apply • Host institutions must provide conditions for the researcher to direct the research and manage its funding • The grant is 'portable' to another host institution, if the grant holder wishes so • Research must be carried out in one of the 28 EU member states or associated countries • Canadians are eligible with a requirement to spend 6 months in a European Institution

  12. ERC Types of grants ERC Starting Grantfor young, early-career top researchers (2-7 years after PhD) -up to 2 million euro for a period of 5 years. ERC Consolidator Grantfor already independent excellent researchers (7-12 years after PhD) -up to 2.75 million euro for a period of 5 years. ERC Advanced Grantfor senior research leaders with significant research achievements in the last 10 years -up to 3.5 million euro for a period of 5 years. ERC Proof of Concept Grantsfor ERC grant holders who want to check the market and/or innovation potential of research results from ERC-projects -up to 150,000 euro for a period of 12 months. ERC Synergy Grantsfor small groups of individual researchers -up to 15 million euro for a period up to 6 years.

  13. Future and Emerging Technologies • FET Flagship • Science-driven, large-scale, multidisciplinary research initiatives oriented towards a unifying goal • Long term commitment (10 years) • Ensuring the continuation of the two flagships after the ramp-up phase (2013-2016): • Human Brain Project – www.humanbrainproject.eu • Graphene – www.graphene-flagship.eu • 20-30 new and full partners added to each flagship • Approximately 9M Euros in each flagship for 2014-2016

  14. Marie Skłodowska-Curie actions • 6,162 million euro over the period 2014-2020 • Support the career development and training of researchers (with a focus on innovation skills) in all scientific disciplines • Types: • Innovative Training Networks (ITN) • Individualfellowships (IF) • Research and Innovation Staff Exchanges (RISE) • COFUND

  15. Industrial Leadership • To speed up development of the technologies and innovations • Specific objectives: • Leadership in enabling and industrial technologies (LEIT) • Biotechnology • Nanotechnologies • Innovation in SME

  16. Societal Challenge Horizon 2020 – Work Programme 2014-2015 Health, demographic change and wellbeing

  17. Health, Demographic Change and Wellbeing • Goal: to keep older people active and independent for longer and supports the development of new, safer and more effective interventions • 2014-2015: € 1.210 billion (CAD $1,8 billion) • Focus on Personalising health and care with 7 areas identified • Area calls: • 34 topics in the ‘Personalisinghealth and care’ • 16 topics in the ‘co-ordination activities’ call • 8 other actions (implementation only)

  18. Personalising health and care: 7 focus areas Understanding health, ageing & disease Effective health promotion, disease prevention,preparedness and screening Improving diagnosis Innovative treatments and technologies Advancing active and healthy ageing Integrated, sustainable, citizen-centred care Improving health information, data exploitation and providing an evidence base for health policies and regulation

  19. Understanding the call topics: example 'PHC 2 – 2015' 'Specific challenge' 'Scope' 'Expected impact' 'Type of action'

  20. Understanding health, ageing and disease • PHC 1 – 2014 Understanding health, ageing and disease: determinants, risk factors and pathways • Improving risk identification and validation • Better diagnosis, risk-based prevention strategies and policies • PHC 2 – 2015 Understandingdiseases: systemsmedicine • New avenues for understanding the complexity of clinical phenotypes in multifactorial diseases and/or their co-morbidities • PHC 3 – 2015 Understanding common mechanisms of diseases and their relevance in co-morbidities • Integration of pre-clinical and clinical studies for the identification of mechanisms common to several diseases

  21. Effective health promotion, disease prevention, preparedness and screening • PHC 4 – 2015 Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions • Limited to the integration of environment, climate and health sectors • PHC 5 – 2014 Health promotion and disease prevention: translating ‘omics’ into stratified approaches • Validity, utility and cost -effectiveness of ‘omics based health promotion and disease prevention programmes. • PHC 6 – 2014 Evaluating existing screening and prevention programmes • Systematic evaluation (health outcomes, cost effectiveness and health equity) • PHC 7 – 2014 Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens • Pathogen monitoring (identification, comparison, geographical mapping) and predictive models on risk assessments. • Contribute to Global Research Collaboration for Infections Disease Preparedness

  22. Effective health promotion, disease prevention, preparedness and screening (Cont’d) • PHC 8 – 2014 Vaccine development for poverty-related and neglected infectious diseases: Tuberculosis • Capacity for development of TB vaccine, barriers/facilitators for uptake in LMICs • PHC 9 – 2015 Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS • Capacity for development of HIV/AIDS vaccine, barriers/facilitators for uptake in LMICs

  23. Improving Diagnosis • PHC 10 – 2014 Development of new diagnostic tools and technologies: in vitro devices, assays and platforms • Development and application of novel in vitro diagnosis tools and technologies to improve diagnosis, prediction, monitoring, intervention or assessment of therapeutic response • PHC 11 – 2015 Development of new diagnostic tools and technologies: in vivo medical imaging technologies • Development of innovative in vivo imaging tools and technologies to improve diagnosis, prediction, monitoring, image-based intervention or assessment of therapeutic response • PHC 12 –2014/2015: Clinical research for the validation of biomarkers and/or diagnostic medical devices • Three separate phases of which the first consists of a draft business plan and feasibility study • SME Instrument (100% funding)

  24. Innovative Treatments and Technologies • PHC 13 – 2014 New therapies for chronic non-communicable diseases • Clinical trial(s) supporting proof of concept in humans • PHC 14 – 2015 New therapies for rare diseases • Development of new or improved therapeutic approaches or preclinical research, animal model development and good manufacturing practice • PHC 15 – 2014/2015 Clinical research on regenerative medicine • Any disease or condition, but need justification

  25. Innovative Treatments and Technologies (Cont’d) • PHC 16 – 2015 Tools and technologies for advanced therapies • Gene therapy, cell therapy, tissue engineering, regenerative medicine and bio-artificial organs • PHC 17 – 2014 Comparing the effectiveness of existing healthcare interventions in the elderly • Preference on interventions with high public health relevance • PHC 18 – 2015 Establishing effectiveness of health care interventions in the paediatricpopulation • Effectiveness, efficacy and safety of healthcare interventions and the use of health technology assessment method

  26. Advancing active and healthy ageing • PHC 19 –2014 Service robotics within assisted living environments • Modularity, cost-effectiveness, reliability, flexibility • PHC 20 –2014 ICT solutions for independent living with cognitive impairment • Innovation in organisational and business models for service delivery, standardisation and interoperability • PHC 21 – 2015 Early risk detection and intervention • Early detection and minimisation of risks associated with ageing • PHC 22 – 2015 Promoting mental wellbeing in the ageing population • Understanding, prevention, early diagnosis, and treatment of mental conditions and disorders of older people

  27. Integrated, sustainable, citizen-centred care • PHC 23 – 2014 Developing and comparing new models for safe and efficient, prevention oriented health and care system • PHC 24 – 2015 Piloting personalised medicine in health and care systems • PHC 25 – 2015 Advanced ICT systems and services for Integrated Care • PHC 26/27/28 – Self-management of health and disease • (2014) Citizen engagement and mHealth • (2015) Patient empowerment supported by ICT • (2015) Based on predictive computer modelling • PHC 29 (2015) Public procurement of innovative eHealth services

  28. Improving health information, data exploitation and providing an evidence base for health policies and regulation PHC 30 – 2015 Digital representation of health data to improve disease diagnosis and treatment PHC 31 – 2014 Foresight for health policy development and regulation PHC 32 – 2014 Advancing bioinformatics to meet biomedical and clinical needs PHC 33 – 2015 New approaches to improve predictive human safety testing PHC 34 – 2014 eHealthinteroperability

  29. Deadlines for PHC calls (2014) 11th March 2014 (stage one of two stage call) 15th April 2014 (single stage call) 19th August 2014 (stage two of two stage call) PHC 12 (See Conditions for the call)

  30. Co-ordination activities

  31. Co-ordinationActivities HCO 1 – 2014 Support for the European Innovation Partnership on Active & HealthyAgeing HCO 2 – 2015 JPI More Years, BetterLives HCO 3 – 2015 European Reference Networks: Efficient network modelling and validation HCO 4 – 2014 Support for international infectious disease preparedness research HCO 5 – 2014 Global Alliance for ChronicDiseases (GACD) – Type 2 Diabetes (open with LOI deadline of February19, 2014) HCO 6 – 2015 Global Alliance for ChronicDiseases (GACD) – focus to beconfirmed HCO 7 – 2014 Joint Programming on NeurodegenerativeDiseasesResearch (JPND)

  32. Co-ordinationActivities (Con’t) • ERA-NET Rare disease • Focused on implementing the International Rare Diseases Research Consortium (IRDiRC) objectives • Current call with a deadline of April 15, 2015 • ERA-NET: in the area of brain-related diseases and disorders of the nervous system • Current call for "European Research Projects on Neuroinflammation” • Deadline: March 10, 2014 • CIHR: $500k; FRSQ: $500k • ERA-NET Antimicrobialresistance • Call for research projects “InnovaResistance: Innovative approaches to address antibacterial resistance” • Deadline: March 14, 2014 (LOI) • Canada is co-leading (CIHR: $6.2 million in funding) • ERA-NET Cardiovasculardisease

  33. FundingSchemes • Collaborative researchprojects and Innovation Actions • Fundingcanvaryfrom call to call • Fundingcovers 100% of eligibleexpenses + 25% flat rate for overhead (- receipts and subcontractingcosts) • Fundinglimited to a max. of 70% for innovation projects (for NGOs: 100%) • Co-ordination Support Activities (CSA) • Actions that focus on the coordination and networking of projects, programmes and policies (not focused on researchitself)

  34. Rules of participation • Financial Regulations • Eligible costs vs non-eligible costs • Control and audits: simplified and lighter • Intellectual Property Rights • Ownership • Protection • Exploitation • Open Access • Obligatory for scientific publications • To research data (when foreseen in WP and in appropriate areas

  35. Conditions for participation • Open for all legal entities established in third countries and for international organisations. • Minimum conditions • Standard collaborative and innovation actions • At least three legal entities each established in a different Member State or an Associated Country; • ERC, SME instrument, programme co-fund, coordination and support, training and mobility actions: • One legal entity established in a Member State or in an Associated Country. • Additional Conditions • In the work programme or work plan.

  36. Fromthe call to theGRANT Time to prepare the proposal Publication of the calls Submission of proposals Evaluation Finalization of the grant Information on the outcome of the evaluator Signature grant agreement Total of 8 months

  37. All call related documentation is published on the Participant Portal http://ec.europa.eu/research/participants/portal/page/home Howtoapply • User friendly Participant Portal • Electronic submission • No signature needed • Easy to find funding opportunities • Search tool • Proposal evaluated as is • Be an expert: register

  38. Criteria for Evaluation • Three criteria: • Excellence • Impact • Quality and Efficiency • For stage 1: thresholds are 4/5 and 4/5 • For stage 2: thresholds are 4/5, 4/5 and 3/5 with a minimum total of 12

  39. CIHR engagement in Joint Programming Initiatives • NeurodegenerativeDiseases(JPND) • “Third Country” membersince May 4th, 2012 • Current call “European research projects for Cross-Disease Analysis of Pathways related to Neurodegenerative Diseases” • More YearsBetter Life (JPIMYBL) • Canada wasapproved for membership in March 2013 • Preliminarytopics: Quality of life, health and welfare; economicand social production; Sustainablewelfare; Governance and institutions • AntimicrobialResistance (JPIAMR) • Canada is the co-lead, alongwith the EU • First call “InnovativesApproaches to New Antibacterial Drug Discovery ” anticipated for January 2014 • A HealthyDiet for A Healthy Life (JPIHDHL) • Canada wasapproved for membership in December 2013

  40. NCP Contacts Jonathan Nagle Manager, International Relations and Executive Support Jonathan.nagle@cihr-irsc.gc.ca Jacqueline Jorge Policy Analyst, International Relations Jacqueline.jorge@cihr-irsc.gc.ca

  41. Questions?

More Related